Home › Funds › Orbis Allan Gray Ltd › GMAB

Orbis Allan Gray Ltd position in GMAB

GENMAB A/S · Health Care

Orbis Allan Gray Ltd reported holding 10,567,391 shares of GMAB (GENMAB A/S) in its Q3 2026 13F filing — a position valued at US$377.0M, representing 1.25% of its reported portfolio and ranking #30 among its reported holdings. Orbis Allan Gray Ltd has disclosed GMAB holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)10.57M sh
Reported value held$376.99M
Portfolio Weight1.25%
First reportedQ3 2024
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Orbis Allan Gray Ltd's GMAB position evolved

Orbis Allan Gray Ltd first disclosed a stake in GMAB in Q3 2024 at 1,676,793 shares (US$40.9M). The position peaked in Q4 2025 at 14,418,462 shares, worth US$444.1M. Across 9 filings, Orbis Allan Gray Ltd increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 10,567,391 shares valued at US$377.0M — a reduction of -800,770 shares quarter over quarter.. Notable position changes include a 68% increase in Q4 2024 (shares fell 6% over the following quarter), a 103% increase in Q1 2025 (shares rose 6% over the following quarter), a 40% increase in Q3 2025 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 1.68M $40.88M New
Q4 2024 2.82M $58.76M Add
Q1 2025 5.71M $111.82M Add
Q2 2025 7.92M $163.64M Add
Q3 2025 11.08M $339.76M Add
Q4 2025 14.42M $444.09M Add
Q1 2026 12.93M $346.79M Reduce
Q2 2026 11.37M $312.28M Reduce
Q3 2026 10.57M $376.99M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GMAB and 13F data

GMAB (GENMAB A/S) is a Health Care company. 36 other funds we track also report a position in GMAB — the largest reported positions include Paradigm Biocapital Advisors LP (US$504.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$188.6M), Sofinnova Investments, Inc. (US$155.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GMAB

All GMAB fund holders →

FAQ

How long has Orbis Allan Gray Ltd held GMAB?

Orbis Allan Gray Ltd has disclosed GMAB holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Orbis Allan Gray Ltd's current position in GMAB?

As of Q3 2026, Orbis Allan Gray Ltd holds 10.57M shares of GMAB (GENMAB A/S), valued at $376.99M, representing 1.25% of its reported portfolio and ranking #30.

Has Orbis Allan Gray Ltd been buying or selling GMAB?

In the latest 13F filing (Q3 2026), Orbis Allan Gray Ltd reduced its position in GMAB. The position peaked in Q4 2025 at 14.42M shares.

Which other funds hold GMAB?

Other major institutional holders of GMAB include Paradigm Biocapital Advisors LP, DEERFIELD MANAGEMENT COMPANY, L.P., Sofinnova Investments, Inc., among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.